Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) EBITDA (2021 - 2026)

Lucid Diagnostics filings provide 5 years of EBITDA readings, the most recent being $23.4 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 289.47% to $23.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$12.2 million, a 73.55% increase, with the full-year FY2025 number at -$12.2 million, up 73.55% from a year prior.
  • EBITDA hit $23.4 million in Q4 2025 for Lucid Diagnostics, up from -$11.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $23.4 million in Q4 2025 to a low of -$15.0 million in Q4 2022.
  • Median EBITDA over the past 5 years was -$11.5 million (2023), compared with a mean of -$9.5 million.
  • Biggest five-year swings in EBITDA: crashed 235.92% in 2022 and later surged 289.47% in 2025.
  • Lucid Diagnostics' EBITDA stood at -$11.2 million in 2021, then tumbled by 33.22% to -$15.0 million in 2022, then rose by 23.52% to -$11.5 million in 2023, then dropped by 8.05% to -$12.4 million in 2024, then surged by 289.47% to $23.4 million in 2025.
  • The last three reported values for EBITDA were $23.4 million (Q4 2025), -$11.8 million (Q3 2025), and -$11.4 million (Q2 2025) per Business Quant data.